Which has stronger earnings & valuation, ELVN or CADL?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Candel Therapeutics N/A N/A -$38.18M -$1.41 N/A

Is ELVN or CADL more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Candel Therapeutics N/A -76.98% -48.50%

Does the media refer more to ELVN or CADL?

In the previous week, Enliven Therapeutics had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 11 mentions for Enliven Therapeutics and 5 mentions for Candel Therapeutics. Enliven Therapeutics' average media sentiment score of 0.36 beat Candel Therapeutics' score of 0.19 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IDYA or CADL?

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 5 articles in the media. IDEAYA Biosciences' average media sentiment score of 0.98 beat Candel Therapeutics' score of 0.19 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNLI or CADL more profitable?

Denali Therapeutics' return on equity of -55.27% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -55.27% -44.24% Candel Therapeutics N/A -76.98% -48.50%

Does the media refer more to CADL or CDNA?

In the previous week, Candel Therapeutics had 1 more articles in the media than CareDx. MarketBeat recorded 5 mentions for Candel Therapeutics and 4 mentions for CareDx. CareDx's average media sentiment score of 0.28 beat Candel Therapeutics' score of 0.19 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CADL or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -76.98% -48.50% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media refer more to CADL or AMLX?

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 5 mentions for Candel Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.29 beat Candel Therapeutics' score of 0.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Candel Therapeutics (CADL) Competitors

$9.94 +0.28 (+2.90%)

Closing price 04:00 PM Eastern

Extended Trading

$9.91 -0.03 (-0.28%)

As of 04:42 PM Eastern

Compare

CADL vs. ELVN, IDYA, DNLI, CDNA, and AMLX

Should you buy Candel Therapeutics stock or one of its competitors? Candel Therapeutics's main competitors and comparable companies include Enliven Therapeutics (ELVN), IDEAYA Biosciences (IDYA), Denali Therapeutics (DNLI), CareDx (CDNA), and Amylyx Pharmaceuticals (AMLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Candel Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Enliven Therapeutics' return on equity of -18.55% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Candel Therapeutics	N/A	-76.98%	-48.50%

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Enliven Therapeutics currently has a consensus target price of $74.44, indicating a potential upside of 83.23%. Candel Therapeutics has a consensus target price of $20.14, indicating a potential upside of 108.52%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Enliven Therapeutics had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 11 mentions for Enliven Therapeutics and 5 mentions for Candel Therapeutics. Enliven Therapeutics' average media sentiment score of 0.36 beat Candel Therapeutics' score of 0.19 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market.

Summary

Enliven Therapeutics beats Candel Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Candel Therapeutics compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 5 articles in the media. IDEAYA Biosciences' average media sentiment score of 0.98 beat Candel Therapeutics' score of 0.19 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Candel Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.49	-$113.70M	-$1.94	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

IDEAYA Biosciences currently has a consensus target price of $52.69, suggesting a potential upside of 46.12%. Candel Therapeutics has a consensus target price of $20.14, suggesting a potential upside of 108.52%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Candel Therapeutics has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Candel Therapeutics	N/A	-76.98%	-48.50%

IDEAYA Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market.

Summary

IDEAYA Biosciences beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Denali Therapeutics has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market.

In the previous week, Candel Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 0 mentions for Denali Therapeutics. Candel Therapeutics' average media sentiment score of 0.19 beat Denali Therapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Denali Therapeutics	Neutral
Candel Therapeutics	Neutral

Candel Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$3.60M	828.06	-$512.54M	-$2.84	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Denali Therapeutics presently has a consensus price target of $35.85, indicating a potential upside of 92.00%. Candel Therapeutics has a consensus price target of $20.14, indicating a potential upside of 108.52%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Denali Therapeutics' return on equity of -55.27% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Candel Therapeutics	N/A	-76.98%	-48.50%

Summary

Denali Therapeutics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to CareDx?

Candel Therapeutics (NASDAQ:CADL) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

13.9% of Candel Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CareDx has a net margin of 24.23% compared to Candel Therapeutics' net margin of 0.00%. CareDx's return on equity of 2.87% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
CareDx	24.23%	2.87%	2.17%

Candel Therapeutics currently has a consensus target price of $20.14, suggesting a potential upside of 108.52%. CareDx has a consensus target price of $54.00, suggesting a potential downside of 13.20%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Candel Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CareDx	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

Candel Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, CareDx has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

CareDx has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
CareDx	$458.09M	7.03	-$21.35M	$2.07	30.05

In the previous week, Candel Therapeutics had 1 more articles in the media than CareDx. MarketBeat recorded 5 mentions for Candel Therapeutics and 4 mentions for CareDx. CareDx's average media sentiment score of 0.28 beat Candel Therapeutics' score of 0.19 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CareDx beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Candel Therapeutics compare to Amylyx Pharmaceuticals?

Candel Therapeutics (NASDAQ:CADL) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Candel Therapeutics currently has a consensus price target of $20.14, suggesting a potential upside of 108.52%. Amylyx Pharmaceuticals has a consensus price target of $38.86, suggesting a potential upside of 42.86%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Candel Therapeutics has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 5 mentions for Candel Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.29 beat Candel Therapeutics' score of 0.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Amylyx Pharmaceuticals	$87.37M	34.69	-$144.74M	-$1.43	N/A

Summary

Amylyx Pharmaceuticals beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$760.61M	$3.89B	$7.19B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-7.05	13.54	274.47	26.16
Price / Sales	N/A	1,185.17	585.00	81.25
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	10.46	17.18	11.21	6.34
Net Income	-$38.18M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.36%	-1.17%	-0.83%	-1.36%
1 Month Performance	-18.32%	-9.68%	-5.42%	-4.29%
1 Year Performance	51.76%	10.04%	4.36%	-0.33%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	2.6863 of 5 stars	$9.94 +2.9%	$20.14 +102.6%	+53.3%	$760.61M	N/A	N/A	55
ELVN Enliven Therapeutics	2.9002 of 5 stars	$46.32 +0.7%	$75.00 +61.9%	+100.0%	$3.38B	N/A	N/A	67	Analyst Forecast
IDYA IDEAYA Biosciences	3.3956 of 5 stars	$37.91 -0.8%	$52.69 +39.0%	+34.4%	$3.37B	$218.71M	N/A	145	News Coverage Insider Trade
DNLI Denali Therapeutics	2.0459 of 5 stars	$20.75 -1.1%	$35.85 +72.7%	+19.3%	$3.35B	$330.53M	N/A	507	News Coverage
CDNA CareDx	2.3497 of 5 stars	$64.84 +0.4%	$54.00 -16.7%	+320.6%	$3.34B	$379.80M	31.20	765

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. ELVN, IDYA, DNLI, CDNA, and AMLX

How does Candel Therapeutics compare to Enliven Therapeutics?

Summary

How does Candel Therapeutics compare to IDEAYA Biosciences?

Summary

How does Candel Therapeutics compare to Denali Therapeutics?

Summary

How does Candel Therapeutics compare to CareDx?

Summary

How does Candel Therapeutics compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. ELVN, IDYA, DNLI, CDNA, and AMLX

How does Candel Therapeutics compare to Enliven Therapeutics?

Is ELVN or CADL more profitable?

Do institutionals and insiders believe in ELVN or CADL?

Do analysts recommend ELVN or CADL?

Does the media refer more to ELVN or CADL?

Which has stronger earnings & valuation, ELVN or CADL?

Which has more risk and volatility, ELVN or CADL?

Summary

How does Candel Therapeutics compare to IDEAYA Biosciences?

Does the media favor IDYA or CADL?

Do insiders & institutionals believe in IDYA or CADL?

Which has better earnings and valuation, IDYA or CADL?

Do analysts recommend IDYA or CADL?

Is IDYA or CADL more profitable?

Which has more risk & volatility, IDYA or CADL?

Summary

How does Candel Therapeutics compare to Denali Therapeutics?

Which has more risk and volatility, DNLI or CADL?

Does the media favor DNLI or CADL?

Which has stronger valuation & earnings, DNLI or CADL?

Do analysts rate DNLI or CADL?

Do institutionals & insiders believe in DNLI or CADL?

Is DNLI or CADL more profitable?

Summary

How does Candel Therapeutics compare to CareDx?

Do insiders and institutionals hold more shares of CADL or CDNA?

Is CADL or CDNA more profitable?

Do analysts prefer CADL or CDNA?

Which has more risk and volatility, CADL or CDNA?

Which has higher valuation and earnings, CADL or CDNA?

Does the media refer more to CADL or CDNA?

Summary

How does Candel Therapeutics compare to Amylyx Pharmaceuticals?

Do insiders & institutionals hold more shares of CADL or AMLX?

Do analysts recommend CADL or AMLX?

Which has more volatility & risk, CADL or AMLX?

Is CADL or AMLX more profitable?

Does the media refer more to CADL or AMLX?

Which has higher valuation & earnings, CADL or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools